Clinical trial NCT00005301 - References

HIV Infections — Transfusion Safety Study (TSS)

Citation(s)

•   Adams M, Lee TH, Busch MP, Heitman J, Marshall GJ, Gjerset GF, Mosley JW
  Rapid freezing of whole blood or buffy coat samples for polymerase chain reaction and cell culture analysis: application to detection of human immunodeficiency virus in blood donor and recipient repositories. The Transfusion Safety Study Group. Transfusion. 1993 Jun;33(6):504-8.
•   Aledort LM, Hilgartner MW, Pike MC, Gjerset GF, Koerper MA, Lian EY, Lusher JM, Mosley JW
  Variability in serial CD4 counts and relation to progression of HIV-I infection to AIDS in haemophilic patients. Transfusion Safety Study Group. BMJ. 1992 Jan 25;304(6821):212-6.
•   Aledort LM, Operskalski EA, Dietrich SL, Koerper MA, Gjerset GF, Lusher JM, Lian EC, Mosley JW
  Low CD4+ counts in a study of transfusion safety. The Transfusion Safety Study Group. N Engl J Med. 1993 Feb 11;328(6):441-2. Erratum in: N Engl J Med 1993 Apr 15;328(15):1128.
•   Aledort LM
  Blood products and immune changes: impacts without HIV infection. Semin Hematol. 1988 Apr;25(2 Suppl 1):14-9.
•   Bishop PC, Boone D, Parker JW
  Immunophenotypes by flow cytometry: a longitudinal study in healthy individuals. Diagn Clin Immunol. 1988;5(5):232-40.
•   Brown NA, Kovacs A, Lui CR, Hur C, Zaia JA, Mosley JW
  Prevalence of antibody to human herpesvirus 6 among blood donors infected with HIV. Lancet. 1988 Nov 12;2(8620):1146.
•   Buckley JD, Pike MC, Mosley JW
  Statistical approaches to evaluating prognostic indices in HIV infection. The Transfusion Safety Study Group. AIDS. 1991 Nov;5(11):1398.
•   Busch MP, Donegan E, Stuart M, Mosley JW
  Donor HIV-1 p24 antigenaemia and course of infection in recipients Transfusion Safety Study Group. Lancet. 1990 Jun 2;335(8701):1342.
•   Busch MP, Henrard DR, Hewlett IK, Mehaffey WF, Epstein JS, Allain JP, Lee TH, Mosley JW
  Poor sensitivity, specificity, and reproducibility of detection of HIV-1 DNA in serum by polymerase chain reaction. The Transfusion Safety Study Group. J Acquir Immune Defic Syndr. 1992;5(9):872-7.
•   Busch MP, Operskalski EA, Mosley JW, Lee TH, Henrard D, Herman S, Sachs DH, Harris M, Huang W, Stram DO
  Factors influencing human immunodeficiency virus type 1 transmission by blood transfusion. Transfusion Safety Study Group. J Infect Dis. 1996 Jul;174(1):26-33.
•   Busch MP, Operskalski EA, Mosley JW, Stevens CE, Schiff ER, Kleinman SH, Lee H, Lee M, Harris M
  Epidemiologic background and long-term course of disease in human immunodeficiency virus type 1-infected blood donors identified before routine laboratory screening. Transfusion Safety Study Group. Transfusion. 1994 Oct;34(10):858-64.
•   Busch MP, Taylor PE, Lenes BA, Kleinman SH, Stuart M, Stevens CE, Tomasulo PA, Allain JP, Hollingsworth CG, Mosley JW
  Screening of selected male blood donors for p24 antigen of human immunodeficiency virus type 1. The Transfusion Safety Study Group. N Engl J Med. 1990 Nov 8;323(19):1308-12.
•   Busch MP, Young MJ, Samson SM, Mosley JW, Ward JW, Perkins HA
  Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening. The Transfusion Safety Study Group. Transfusion. 1991 Jan;31(1):4-11.
•   Diaz RS, Sabino EC, Mayer A, deOliveira CF, Mosley JW, Busch MP
  Lack of dual HIV infection in a transfusion recipient exposed to two seropositive blood components. AIDS Res Hum Retroviruses. 1996 Sep 1;12(13):1291-5.
•   Diaz RS, Sabino EC, Mayer A, Mosley JW, Busch MP
  Dual human immunodeficiency virus type 1 infection and recombination in a dually exposed transfusion recipient. The Transfusion Safety Study Group. J Virol. 1995 Jun;69(6):3273-81.
•   Diaz RS, Zhang L, Busch MP, Mosley JW, Mayer A
  Divergence of HIV-1 quasispecies in an epidemiologic cluster. AIDS. 1997 Mar 15;11(4):415-22.
•   Dietrich SL, Mosley JW, Lusher JM, Hilgartner MW, Operskalski EA, Habel L, Aledort LM, Gjerset GF, Koerper MA, Lewis BH, et al
  Transmission of human immunodeficiency virus type 1 by dry-heated clotting factor concentrates. Transfusion Safety Study Group. Vox Sang. 1990;59(3):129-35.
•   Donegan E, Busch MP, Galleshaw JA, Shaw GM, Mosley JW
  Transfusion of blood components from a donor with human T-lymphotropic virus type II (HTLV-II) infection. The Transfusion Safety Study Group. Ann Intern Med. 1990 Oct 1;113(7):555-6.
•   Donegan E, Pell P, Lee H, Shaw GM, Mosley JW
  Transmission of human T-lymphotropic virus type I by blood components from a donor lacking anti-p24: a case report. The Transfusion Safety Study Group. Transfusion. 1992 Jan;32(1):68-71.
•   Donegan E, Stuart M, Niland JC, Sacks HS, Azen SP, Dietrich SL, Faucett C, Fletcher MA, Kleinman SH, Operskalski EA, et al
  Infection with human immunodeficiency virus type 1 (HIV-1) among recipients of antibody-positive blood donations. Ann Intern Med. 1990 Nov 15;113(10):733-9.
•   Edwards VM, Mosley JW
  Reproducibility in quality control of protein (Western) immunoblot assay for antibodies to human immunodeficiency virus. Am J Clin Pathol. 1989 Jan;91(1):75-8.
•   Fletcher MA, Azen SP, Adelsberg B, Gjerset G, Hassett J, Kaplan J, Niland JC, Odom-Maryon T, Parker JW, Stites DP, et al
  Immunophenotyping in a multicenter study: the Transfusion Safety Study experience. Clin Immunol Immunopathol. 1989 Jul;52(1):38-47.
•   Fletcher MA, Baron GC, Ashman MR, Fischl MA, Klimas NG
  Use of whole blood methods in assessment of immune parameters in immunodeficiency states. Diagn Clin Immunol. 1987;5(2):69-81.
•   Fletcher MA, Gjerset GF, Hassett J, Donegan E, Parker JW, Mosley JW
  Lymphocyte immunophenotypes among anti-HTLV-I/II-positive blood donors and recipients. The Transfusion Safety Study Group. J Acquir Immune Defic Syndr. 1991;4(6):628-32.
•   Fletcher MA, Mosley JW, Hassett J, Gjerset GF, Kaplan J, Parker JW, Donegan E, Lusher JM, Lee H
  Effect of age on human immunodeficiency virus type 1-induced changes in lymphocyte populations among persons with congenital clotting disorders. Transfusion Safety Study Group. Blood. 1992 Aug 1;80(3):831-40.
•   Gjerset GF, Pike MC, Mosley JW, Hassett J, Fletcher MA, Donegan E, Parker JW, Counts RB, Zhou Y, Kasper CK, et al
  Effect of low- and intermediate-purity clotting factor therapy on progression of human immunodeficiency virus infection in congenital clotting disorders. Transfusion Safety Study Group. Blood. 1994 Sep 1;84(5):1666-71.
•   Gjerset GF, Vyas GN, Bhat R, Operskalski EA
  Phenotypes for group-specific component among patients exposed to human immunodeficiency virus by transfusions. J Infect Dis. 1988 Mar;157(3):609-10.
•   Govindarajan S, Edwards VM, Stuart ML, Operskalski EA, Mosley JW and the Transfusion Safety Study Group: Influence of Human Immunodeficiency Virus Infection Upon Expression of Chronic Hepatitis B and D Virus Infections
  In: Zuckerman AJ (Ed), Viral Hepatitis and Liver Disease, Alan R Liss, Inc, New York, pp 210-214, 1988
•   Hassett J, Gjerset GF, Mosley JW, Fletcher MA, Donegan E, Parker JW, Counts RB, Aledort LM, Lee H, Pike MC
  Effect on lymphocyte subsets of clotting factor therapy in human immunodeficiency virus-1-negative congenital clotting disorders. The Transfusion Safety Study Group. Blood. 1993 Aug 15;82(4):1351-7.
•   Hilgartner M
  Results of the transfusion safety study. Ann Hematol. 1994;68 Suppl 3:S59.
•   Hilgartner MW, Buckley JD, Operskalski EA, Pike MC, Mosley JW
  Purity of factor VIII concentrates and serial CD4 counts. The Transfusion Safety Study Group. Lancet. 1993 May 29;341(8857):1373-4.
•   Hilgartner MW
  Changes in CD4 count relative to product usage: findings from the transfusion safety study. Semin Hematol. 1993 Oct;30(4 Suppl 5):7-9. Review.
•   Kaplan J, Sarnaik I, Lusher J
  Increase in Leu 2+ Leu 7+ lymphocytes in HIV 1-seropositive patients with hemophilia repeatedly treated with clotting factor concentrates. Clin Immunol Immunopathol. 1988 Mar;46(3):337-41.
•   Kedes DH, Operskalski E, Busch M, Kohn R, Flood J, Ganem D
  The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nat Med. 1996 Aug;2(8):918-24. Erratum in: Nat Med 1996 Sep;2(9):1041.
•   Kleinman SH, Niland JC, Azen SP, Operskalski EA, Barbosa LH, Chernoff AI, Edwards VM, Lenes BA, Marshall GJ, Nemo GJ, et al
  Prevalence of antibodies to human immunodeficiency virus type 1 among blood donors prior to screening. The Transfusion Safety Study/NHLBI Donor Repository. Transfusion. 1989 Sep;29(7):572-80.
•   Lang DJ, Kovacs AA, Zaia JA, Doelkin G, Niland JC, Aledort L, Azen SP, Fletcher MA, Gauderman J, Gjerset GJ, et al
  Seroepidemiologic studies of cytomegalovirus and Epstein-Barr virus infections in relation to human immunodeficiency virus type 1 infection in selected recipient populations. Transfusion Safety Study Group. J Acquir Immune Defic Syndr. 1989;2(6):540-9.
•   McClure E, Gaynor S, Veiga-Benach A, O'Neil D, and the Transfusion Safety Study Group: Notification of Recipients of Human Immunodeficiency Virus (HIV) Antibody Positive Transfusions
  Nursing, Jan; 10, 1989
•   Miller K, Donegan E, Curran P, Shelley TJ
  Effects of counselling on knowledge about HIV-1 among transfusion recipients and their partners. Transfusion Safety Study Group. AIDS Care. 1990;2(2):155-62.
•   Mosley JW, Nowicki M, Kleinman SH, Dietrich SL and the Transfusion Safety Study Group: Reactivation of Hepatitis B
  Lancet, 1:1083-1084, 1989
•   Mosley JW, Nowicki MJ, Kasper CK, Donegan E, Aledort LM, Hilgartner MW, Operskalski EA
  Hepatitis A virus transmission by blood products in the United States. Transfusion Safety Study Group. Vox Sang. 1994;67 Suppl 1:24-8.
•   Mosley JW
  Has hepatitis A virus been transmitted by clotting factor concentrates among hemophiliacs in the United States? Vox Sang. 1994;67 Suppl 4:12-5; discussion 24-6. Review.
•   Mosley JW
  Low CD4+ counts in a study of transfusion safety: correction. N Engl J Med. 1993 Apr 15;328(15):1128.
•   Niland-Weiss J, Azen SP, Odom-Maryon T, Lui F, Hagerty C
  A microcomputer-based distributed data management system for a large cooperative study of transfusion associated acquired immunodeficiency syndrome. Comput Biomed Res. 1987 Jun;20(3):225-43.
•   Norman GL, Barker SS, Rasheed S
  Immunoblot reactivity of a non-HIV protein with human sera. Transfusion Safety Study Group. J Clin Lab Anal. 1989;3(3):148-51.
•   Odom-Maryon T, Langholz B, Niland J, Azen S
  Generalization of normal discriminant analysis using Fourier series density estimators. Transfusion Safety Study Group. Stat Med. 1991 Mar;10(3):473-85.
•   Operskalski EA, Busch MP, Mosley JW, Stram DO
  Comparative rates of disease progression among persons infected with the same or different HIV-1 strains. The Transfusion Safety Study Group. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Jun 1;15(2):145-50.
•   Operskalski EA, Mosley JW, Busch MP, Stram DO
  Influences of age, viral load, and CD4+ count on the rate of progression of HIV-1 infection to AIDS. Transfusion Safety Study Group. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Jul 1;15(3):243-4.
•   Operskalski EA, Schiff ER, Kleinman SH, Busch M, Taylor PE, Parks WP, Lee H, Tomasulo PA, Donegan E, Stuart M, et al
  Epidemiologic background of blood donors with antibody to human T-cell lymphotropic virus. Transfusion Safety Study Group. Transfusion. 1989 Oct;29(8):746-8.
•   Operskalski EA, Stram DO, Busch MP, Huang W, Harris M, Dietrich SL, Schiff ER, Donegan E, Mosley JW
  Role of viral load in heterosexual transmission of human immunodeficiency virus type 1 by blood transfusion recipients. Transfusion Safety Study Group. Am J Epidemiol. 1997 Oct 15;146(8):655-61.
•   Operskalski EA, Stram DO, Lee H, Zhou Y, Donegan E, Busch MP, Stevens CE, Schiff ER, Dietrich SL, Mosley JW
  Human immunodeficiency virus type 1 infection: relationship of risk group and age to rate of progression to AIDS. Transfusion Safety Study Group. J Infect Dis. 1995 Sep;172(3):648-55.
•   Parker JW, Adelsberg B, Azen SP, Boone D, Fletcher MA, Gjerset GF, Hassett J, Kaplan J, Niland JC, Odom-Maryon T, et al
  Leukocyte immunophenotyping by flow cytometry in a multisite study: standardization, quality control, and normal values in the Transfusion Safety Study. The Transfusion Safety Study Group. Clin Immunol Immunopathol. 1990 May;55(2):187-220.
•   Parks WP, Lenes BA, Tomasulo PA, Schiff ER, Parks ES, Shaw GM, Lee H, Yan HQ, Lai S, Hollingsworth CG, et al
  Human T-cell lymphotropic virus infection among blood donors in south Florida. The Transfusion Safety Study Group. J Acquir Immune Defic Syndr. 1991;4(1):89-96.
•   Perkins HA, Cordell R, Bueno C, Shiota J, Hitchcock B
  The progressive decrease in the proportion of blood donors with antibody to the human immunodeficiency virus (HIV). Transfusion. 1987 Nov-Dec;27(6):502-3.
•   Vasil'eva VF, Vorob'eva KP
  [Study of magnesium transport in the dog kidney by the method of stopping urine emission in chronic experiments]. Fiziol Zh SSSR Im I M Sechenova. 1975 Jan;61(1):130-5. Russian.
•   Wilkinson DA, Operskalski EA, Busch MP, Mosley JW, Koup RA
  A 32-bp deletion within the CCR5 locus protects against transmission of parenterally acquired human immunodeficiency virus but does not affect progression to AIDS-defining illness. J Infect Dis. 1998 Oct;178(4):1163-6.
•   Wong WY, Powars DR, Operskalski EA, Hassett J, Parker JW, Sarnaik S, Pegelow CH, Hilgartner MW, Johnson CS, Zhou Y, et al
  Blood transfusions and immunophenotypic alterations of lymphocyte subsets in sickle cell anemia. The Transfusion Safety Study Group. Blood. 1995 Apr 15;85(8):2091-7.
•   Wong WY, Zhou Y, Operskalski EA, Hassett J, Powars DR, Mosley JW
  Hematologic profile and lymphocyte subpopulations in hemoglobin SC disease: comparison with hemoglobin SS and black controls. The Transfusion Safety Study Group. Am J Hematol. 1996 Jul;52(3):150-4.
•   Zhang L, Diaz RS, Ho DD, Mosley JW, Busch MP, Mayer A
  Host-specific driving force in human immunodeficiency virus type 1 evolution in vivo. J Virol. 1997 Mar;71(3):2555-61.

Details for clinical trial NCT00005301